ANB033
ANB033 is a novel anti-CD122 antagonist that targets the shared beta subunit of the receptors for IL-15 and IL-2
Phase 1b cohort in celiac disease initiated
Virtual investor event on Oct. 14th
Anti-CD122 antagonist reduces pathogenic T cells and NK cells
CD122 is a shared beta subunit of the receptors for IL-15 and IL-2
CD122 antagonist mAb will potently inhibit IL-15 and IL-2 biology
CD122 antagonist mAb will potently inhibit IL-15 and IL-2 biology
Both IL-15 and IL-2 mediate:
- Proliferation and survival of T cell subsets, particularly CD8+ TEMRA, and NK cells
- Inflammatory cytokine secretion (IFNγ) during T cell activation
ANB033 reduces pathogenic T cells
- Preferentially inhibits lower affinity dimeric IL-2 receptor complex
ANB033 has targeted reduction of CD122 expressing TRM cells
- TRM cells require IL-15 for survival
- May potentially drive durable response
Hare E, et al. FOCIS 2023. June 2023
ANB033 potently targets multiple pathogenic drivers of celiac disease
IL-15 signaling antagonism
- Reduces tissue damage by IL-15-mediated accumulation and killing activity of CD122+ intra-epithelial lymphocytes (IEL)
IL-2 signaling antagonism
- Modulates other specific immune pathways active during immune response to gluten in individuals with celiac disease, including upstream CD4 T cell-derived IFNγ, IL-2 and downstream B cell-mediated antibody responses
Further information on ANB033 MoA, preclinical data, Phase 1a data, and celiac study design to be disclosed at Oct. 14th investor event
To access scientific publications on this topic, please click here.